- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 901975, 7 pages
Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study
1Gerinnungszentrum Rhein-Ruhr (GZRR), 47051 Duisburg, Germany
2Department of Pediatrics, University Hospital of Munich, 80337 Munich, Germany
3Department of Pediatric Hematology/Oncology, University Hospital of Frankfurt, 60590 Frankfurt, Germany
4Outpatient Hemophilia Treatment Center, 23564 Lubbock, Germany
5Department of Pediatric Hematology/Oncology, Charite, 13353 Berlin, Germany
6The Israel National Hemophilia Centre, Sheba Medical Centre, Tel-Hashomer and the Sackler Medical School, Tel Aviv, 52621 Tel-Hashomer, Israel
7Department of Pediatrics, University Hospital of Münster, 48149 Münster, Germany
8Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada L85 4K1
9Thrombosis & Hemophilia Treatment Center, Institute of Clinical Chemistry, University Hospital of Kiel, 24105 Kiel, Germany
Received 25 June 2013; Revised 30 August 2013; Accepted 31 August 2013
Academic Editor: Saulius Butenas
Copyright © 2013 Susan Halimeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. Gringeri, L. G. Mantovani, L. Scalone, and P. M. Mannucci, “Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS study group,” Blood, vol. 102, no. 7, pp. 2358–2363, 2003.
- S. Paisley, J. Wight, E. Currie, and C. Knight, “The management of inhibitors in haemophilia A: introduction and systematic review of current practice,” Haemophilia, vol. 9, no. 4, pp. 405–417, 2003.
- S. C. Gouw, J. G. Van Der Bom, and H. M. Van Den Berg, “Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study,” Blood, vol. 109, no. 11, pp. 4648–4654, 2007.
- S. C. Gouw, H. M. Van Den Berg, J. Oldenburg et al., “F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis,” Blood, vol. 119, no. 12, pp. 2922–2934, 2012.
- A. Iorio, S. Halimeh, S. Holzhauer et al., “Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review,” Journal of Thrombosis and Haemostasis, vol. 8, no. 6, pp. 1256–1265, 2010.
- A. Iorio, E. Marchesini, M. Marcucci, K. Stobart, and A. K. Chan, “Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B,” Cochrane Database of Systematic Reviews, vol. 9, Article ID CD003429, 2011.
- S. C. Gouw, J. van der Bom, R. Ljung, et al., “Factor VIII products and inhibitor development in severe hemophilia A,” New England Journal of Medicine, vol. 368, pp. 231–239, 2013.
- E. Von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke, “The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies,” PLOS Medicine, vol. 4, no. 19, article e296, 2007.
- T. Strauss, A. Lubetsky, B. Ravid et al., “Recombinant factor concentrates may increase inhibitor development: a single centre cohort study,” Haemophilia, vol. 17, no. 4, pp. 625–629, 2011.
- C. E. Ettingshausen, S. Halimeh, K. Kurnik et al., “Hemophilia phenotype is dependent on the presence of prothrombotic risk factors,” Thrombosis and Haemostasis, vol. 85, no. 2, pp. 218–220, 2001.
- K. Kurnik, W. Kreuz, S. Horneff et al., “Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children—results of a multicenter study,” Haematologica, vol. 92, no. 7, pp. 982–985, 2007.
- W. Kreuz, C. E. Ettingshausen, M. Funk, S. Pons, H. Schmidt, and B. Kornhuber, “Prevention of joint damage in hemophilic children with early prophylaxis,” Orthopade, vol. 28, no. 4, pp. 341–346, 1999.
- R. Ljung, “Paediatric care of the child with haemophilia,” Haemophilia, vol. 8, no. 3, pp. 178–182, 2002.
- M. Kern, V. Blanchette, A. M. Stain, T. R. Einarson, and B. M. Feldman, “Clinical and cost implications of target joints in Canadian boys with severe hemophilia A,” Journal of Pediatrics, vol. 145, no. 5, pp. 628–634, 2004.
- K. Kurnik, C. Bidlingmaier, W. Engl, H. Chehadeh, B. Reipert, and G. Auerswald, “New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development,” Haemophilia, vol. 16, no. 2, pp. 256–262, 2010.
- K. Fischer, D. Lewandowski, H. Marijke van den Berg, and M. P. Janssen, “Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project,” Haemophilia, vol. 18, no. 3, pp. e241–e246, 2012.
- P. Peduzzi, J. Concato, E. Kemper, T. R. Holford, and A. R. Feinstem, “A simulation study of the number of events per variable in logistic regression analysis,” Journal of Clinical Epidemiology, vol. 49, no. 12, pp. 1373–1379, 1996.
- A. Iorio, M. W. Skinner, and M. Makris, “Factor VIII products and inhibitors in severe hemophilia A,” New England Journal of Medicine, vol. 368, no. 15, article 1456.
- C. M. Kessler and A. Ioroi, “The Rodin (Research Of Determinants of Inhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters,” Haemophilia, no. 19, pp. 351–354, 2013.